Cite
HARVARD Citation
Duso, B. et al. (2018). Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. Expert opinion on pharmacotherapy. pp. 299-305. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Duso, B. et al. (2018). Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. Expert opinion on pharmacotherapy. pp. 299-305. [Online].